← SynDRA
BRIVANIB
SynDRA canonical compound SYN0006153 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | KDR |
|---|
| Mechanism of action | VEGFR inhibitor |
|---|
All known targets
- KDR
- FGFR1
- FLT1
- FGFR2
- FGFR3
- FLT4
- FGFR4
- CYP3A4
- KCNH2
Mechanisms of action (all sources)
- FGFR inhibitor
- VEGFR inhibitor
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor inhibitor
- FGFR1 INHIBITOR
- FGFR4 INHIBITOR
- FGFR2 INHIBITOR
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
- KDR INHIBITOR
- KDR MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SLK
- EPHB6
- TNIK
- RIPK2
- EPHA7
- TIE1
- MAP2K5
- TEK
- BLK
- MINK1
- HCK
- PDGFRA
- SYK
- CSF1R
- STK32B
- RET
- STK33
- LCK
- STRADA
- STK35
- PDGFRB
- EPHA6
- KIT
- MAP4K5
- DDR1
- MAP3K19
- MAP4K4
- SRC
- EGFR
- ABL1
- YES1
- ABL2
- STK10
- PAK1
- PAICS
- OXSR1
- OPA1
- PIK3C2B
- PI4KB
- PASK
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- BMS-540215
- BRIVANIB (BMS-540215)
- CPD 12
- BMS 540215
- Brivanib (BMS-540215)
- UNII-DDU33B674I
- Brivanib [USAN]
- BMS540215
- DDU33B674I
- CHEMBL377300
- (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol
- Brivanib (USAN)
- (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL
- (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
- CHEBI:167686
- RefChem:121442
- DTXCID60137785
- VEGFR2 Inhibitor BMS-540215
- MFCD13194684
- Brivanib (Standard)
- BRIVANIB [MI]
- BRIVANIB [WHO-DD]
- Brivanib,BMS-540215
- MLS006011288
- GTPL5671
- orb1689660
- SCHEMBL1227589
- SCHEMBL29354510
- CHEBI:94562
- EX-A011
- GLXC-90426
- BDBM50184807
- HY-10337R
- NSC799368
- s1084
- AKOS015920386
- AKOS015949459
- AC-5252
Look up BRIVANIB in the interactive SynDRA portal →